English

ABVC BIOPHARMA, INC.

EDGAR

ABVC Quarterly report (10-Q) · filed 2026-08-12

Annual consolidated revenue for 2024: about USD 509.6K, using the latest reported figures. The previous period, 2023, was about USD 152.4K.

Inspect reported changes Compare with another company Historical disclosures Search filings Segments

Watchlist

Latest quarter

Revenue

796 thousand USD

2025 Q3 · USD

Exact inputs and evidence

Revenue: 795950 USD Source

Operating margin

-246.79%

2025-09-30 · %

Exact inputs and evidence

Operating Income: -4952348 USD Source
Operating Income: -2987988 USD Source
Revenue: 795950 USD Source

Operating cash flow

-965 thousand USD

2025 Q3 · USD

Exact inputs and evidence

Operating Cash Flow: -2398717 USD Source
Operating Cash Flow: -1434007 USD Source

Cash and cash equivalents: 31.9 thousand uref_614503522 2026-06-30 Source
Exact value

31944 uref_614503522
Long-term debt including current maturities: 124 thousand USD 2020-09-30 Source
Exact value

124400 USD
Shares outstanding: 25.8 million uref_2135577366 2026-06-30 Source
Exact value

25767664 uref_2135577366

Trailing twelve months

The four most recent complete quarters added together. This gives a full-year view that includes the latest quarterly results.

Operating cash flow

-3.34 million USD

2025-04-01 – 2026-03-31

Exact inputs and evidence

Operating cash flow: -1434007 USD · 2025-01-01 – 2025-06-30 Source
Operating cash flow: -539833 USD · 2025-01-01 – 2025-03-31 Source
Operating cash flow: -2398717 USD · 2025-01-01 – 2025-09-30 Source
Operating cash flow: -1434007 USD · 2025-01-01 – 2025-06-30 Source
Operating cash flow: -2986299 USD · 2025-01-01 – 2025-12-31 Source
Operating cash flow: -2398717 USD · 2025-01-01 – 2025-09-30 Source
Operating cash flow: -894243 USD · 2026-01-01 – 2026-03-31 Source

Includes later revisions to earlier periods. Annual charts exclude incomplete years.

Latest filing recorded: 2026-08-12.

Financial data available through: 2024-12-31.

Financial coverage is incomplete. Newer filings are recorded, but comparable financial figures for those periods are not available here yet.

Coverage by financial measure

Revenue: 8 of 11 periods available· newest 2024-12-31
Operating income: 10 of 11 periods available· newest 2024-12-31
Net income: 11 of 11 periods available· newest 2024-12-31
Operating cash flow: 11 of 11 periods available· newest 2024-12-31
Capital expenditure: 3 of 11 periods available· newest 2023-12-31
Total assets: 8 of 11 periods available· newest 2024-12-31
Total liabilities: 8 of 11 periods available· newest 2024-12-31
Current assets: 8 of 11 periods available· newest 2024-12-31
Current liabilities: 8 of 11 periods available· newest 2024-12-31
Cash and cash equivalents: 8 of 11 periods available· newest 2024-12-31
long term debt: No compatible figures in this window
Shares outstanding: 8 of 11 periods available· newest 2024-12-31

Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.

What changed year over year

Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.

Revenue
+234.3%

Prior period

USD 152,430

2023-01-01 – 2023-12-31
Current period

USD 509,589

2024-01-01 – 2024-12-31

Exact inputs and evidence

509589 − 152430 = 357159 USD

152430 USD · 2023-01-01 – 2023-12-31
Inspect prior input Prior source
509589 USD · 2024-01-01 – 2024-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Revenue · ABVC BIOPHARMA, INC. · 2024-12-31 ABVC BIOPHARMA, INC. (edgar:1173313) Year-over-year change in Revenue: 357159 USD Concept: fundies:Revenue Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T15:09:01Z Snapshot: 35d14e8488b6344682b1fece4ae225e14dc7c4a5c357b1531821187b936b408c Dimensions: Consolidated View: https://fundies.io/companies/edgar/1173313?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:Revenue: 509589 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1173313/000121390026023063/ea0278313-10k_abvcbio.htm#1176479 Filing: 000121390026023063 Input fundies:Revenue: 152430 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1173313/000121390025032118/ea0232540-10k_abvcbio.htm#1212670 Filing: 000121390025032118
The citation records this snapshot. The page link may show a newer release later.
Net income
+USD 2.89 million

Prior period

−USD 7.79 million

2023-01-01 – 2023-12-31
Current period

−USD 4.9 million

2024-01-01 – 2024-12-31

Exact inputs and evidence

-4902878 − -7788050 = 2885172 USD

-7788050 USD · 2023-01-01 – 2023-12-31
Inspect prior input Prior source
-4902878 USD · 2024-01-01 – 2024-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Net income · ABVC BIOPHARMA, INC. · 2024-12-31 ABVC BIOPHARMA, INC. (edgar:1173313) Year-over-year change in Net income: 2885172 USD Concept: fundies:NetIncome Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T15:09:01Z Snapshot: 35d14e8488b6344682b1fece4ae225e14dc7c4a5c357b1531821187b936b408c Dimensions: Consolidated View: https://fundies.io/companies/edgar/1173313?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:NetIncome: -4902878 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1173313/000121390026023063/ea0278313-10k_abvcbio.htm#1163896 Filing: 000121390026023063 Input fundies:NetIncome: -7788050 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1173313/000121390025032118/ea0232540-10k_abvcbio.htm#1641972 Filing: 000121390025032118
The citation records this snapshot. The page link may show a newer release later.
Operating cash flow
+USD 2.38 million

Prior period

−USD 4.19 million

2023-01-01 – 2023-12-31
Current period

−USD 1.81 million

2024-01-01 – 2024-12-31

Exact inputs and evidence

-1809145 − -4186848 = 2377703 USD

-4186848 USD · 2023-01-01 – 2023-12-31
Inspect prior input Prior source
-1809145 USD · 2024-01-01 – 2024-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Operating cash flow · ABVC BIOPHARMA, INC. · 2024-12-31 ABVC BIOPHARMA, INC. (edgar:1173313) Year-over-year change in Operating cash flow: 2377703 USD Concept: fundies:OperatingCashFlow Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T15:09:01Z Snapshot: 35d14e8488b6344682b1fece4ae225e14dc7c4a5c357b1531821187b936b408c Dimensions: Consolidated View: https://fundies.io/companies/edgar/1173313?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:OperatingCashFlow: -1809145 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1173313/000121390026023063/ea0278313-10k_abvcbio.htm#917076 Filing: 000121390026023063 Input fundies:OperatingCashFlow: -4186848 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1173313/000121390025032118/ea0232540-10k_abvcbio.htm#875555 Filing: 000121390025032118
The citation records this snapshot. The page link may show a newer release later.

Comparable inputs unavailable for: Capital expenditure.

Where revenue goes

How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.

2024 2024-01-01 – 2024-12-31

Revenue USD 509,589 100% of revenue
Cost of revenue USD 763 0.1% of revenue
Operating expenses USD 5.21 million 1,023% of revenue
Operating income −USD 4.71 million −923% of revenue
Tax, interest and other Derived USD 197,636 39% of revenue
Net income −USD 4.9 million −962% of revenue

Cash

Operating cash flow −USD 1.81 million −355% of revenue
Capital expenditure Unavailable An input is unavailable.
Free cash flow Derived Unavailable An input is unavailable.

Share of revenue by period

Net income
Tax, interest and other
Operating costs

2018 Operating loss: operating costs were 40,131% of revenue.
2019 Operating loss: operating costs were 593% of revenue.
2020 Operating loss: operating costs were 1,861% of revenue.
2021 Operating loss: operating costs were 3,390% of revenue.
2022 Operating loss: operating costs were 1,659% of revenue.
2023 Operating loss: operating costs were 4,539% of revenue.
2024 Operating loss: operating costs were 1,023% of revenue.

Values and sources

Revenue breakdown by annual reporting period
Period	Revenue	Operating costs	Operating income	Tax, interest and other	Net income	Free cash flow	Source
2018 2018-01-01 – 2018-12-31	6956	2791519 Derived	-2784563	3279967 Derived	-6064530	Unavailable	Source 2018-01-01 – 2018-12-31: 6956 USD Inspect Revenue Open source 2018-01-01 – 2018-12-31: -2784563 USD Inspect Operating Income Open source 2018-01-01 – 2018-12-31: -6064530 USD Inspect Net Income Open source 2018-01-01 – 2018-12-31: -900531 USD Inspect Operating Cash Flow Open source
2019 2019-01-01 – 2019-12-31	701719	4160497 Derived	-3458778	474462 Derived	-3933240	Unavailable	Source 2019-01-01 – 2019-12-31: 701719 USD Inspect Revenue Open source 2019-01-01 – 2019-12-31: -3458778 USD Inspect Operating Income Open source 2019-01-01 – 2019-12-31: -3933240 USD Inspect Net Income Open source 2019-01-01 – 2019-12-31: -3134526 USD Inspect Operating Cash Flow Open source
2020 2020-01-01 – 2020-12-31	483045	8988821 Derived	-8505776	2087808 Derived	-10593584	Unavailable	Source 2020-01-01 – 2020-12-31: 483045 USD Inspect Revenue Open source 2020-01-01 – 2020-12-31: -8505776 USD Inspect Operating Income Open source 2020-01-01 – 2020-12-31: -10593584 USD Inspect Net Income Open source 2020-01-01 – 2020-12-31: -4563919 USD Inspect Operating Cash Flow Open source
2021 2021-01-01 – 2021-12-31	355797	12061765 Derived	-11705968	1132845 Derived	-12838813	-7615222 Derived	Source 2021-01-01 – 2021-12-31: 355797 USD Inspect Revenue Open source 2021-01-01 – 2021-12-31: -11705968 USD Inspect Operating Income Open source 2021-01-01 – 2021-12-31: -12838813 USD Inspect Net Income Open source 2021-01-01 – 2021-12-31: -7597719 USD Inspect Operating Cash Flow Open source 2021-01-01 – 2021-12-31: 17503 USD Inspect Capital Expenditure Open source
2022 2022-01-01 – 2022-12-31	969783	16084195 Derived	-15114412	1308827 Derived	-16423239	-7518083 Derived	Source 2022-01-01 – 2022-12-31: 969783 USD Inspect Revenue Open source 2022-01-01 – 2022-12-31: -15114412 USD Inspect Operating Income Open source 2022-01-01 – 2022-12-31: -16423239 USD Inspect Net Income Open source 2022-01-01 – 2022-12-31: -7398391 USD Inspect Operating Cash Flow Open source 2022-01-01 – 2022-12-31: 119692 USD Inspect Capital Expenditure Open source
2023 2023-01-01 – 2023-12-31	152430	6919164 Derived	-6766734	1021316 Derived	-7788050	-4208049 Derived	Source 2023-01-01 – 2023-12-31: 152430 USD Inspect Revenue Open source 2023-01-01 – 2023-12-31: -6766734 USD Inspect Operating Income Open source 2023-01-01 – 2023-12-31: -7788050 USD Inspect Net Income Open source 2023-01-01 – 2023-12-31: -4186848 USD Inspect Operating Cash Flow Open source 2023-01-01 – 2023-12-31: 21201 USD Inspect Capital Expenditure Open source
2024 2024-01-01 – 2024-12-31	509589	5214831 Derived	-4705242	197636 Derived	-4902878	Unavailable	Source 2024-01-01 – 2024-12-31: 509589 USD Inspect Revenue Open source 2024-01-01 – 2024-12-31: -4705242 USD Inspect Operating Income Open source 2024-01-01 – 2024-12-31: -4902878 USD Inspect Net Income Open source 2024-01-01 – 2024-12-31: -1809145 USD Inspect Operating Cash Flow Open source

Amounts are exact, in USD.

Growth

Sales over time and how quickly they are changing.

Revenue

Revenue reported for each complete financial period.

USD 509.6K 2024

Values and sources

Revenue values and source evidence
Period	Series	Value(USD)	Source evidence
20152015-09-30	Revenue	3360	Revenue: 3360 Open source
20182018-12-31	Revenue	6956	Revenue: 6956 Open source
20192019-12-31	Revenue	701719	Revenue: 701719 Open source
20202020-12-31	Revenue	483045	Revenue: 483045 Open source
20212021-12-31	Revenue	355797	Revenue: 355797 Open source
20222022-12-31	Revenue	969783	Revenue: 969783 Open source
20232023-12-31	Revenue	152430	Revenue: 152430 Open source
20242024-12-31	Revenue	509589	Revenue: 509589 Open source

Revenue growth

Change in revenue from the same financial period one year earlier.

234.3% 2024

Values and sources

Revenue growth values and source evidence
Period	Series	Value	Source evidence
20152015-09-30	Year over year	No prior comparable period	Revenue: 3360 Open source
20182018-12-31	Year over year	No prior comparable period	Revenue: 6956 Open source
20192019-12-31	Year over year	9,988%	Revenue: 701719 Open source Revenue: 6956 Open source
20202020-12-31	Year over year	-31.2%	Revenue: 483045 Open source Revenue: 701719 Open source
20212021-12-31	Year over year	-26.3%	Revenue: 355797 Open source Revenue: 483045 Open source
20222022-12-31	Year over year	172.6%	Revenue: 969783 Open source Revenue: 355797 Open source
20232023-12-31	Year over year	-84.3%	Revenue: 152430 Open source Revenue: 969783 Open source
20242024-12-31	Year over year	234.3%	Revenue: 509589 Open source Revenue: 152430 Open source

Profit and cash

How much revenue becomes profit, and how much cash operations generate.

Profit margins

Operating income, net income and free cash flow as a share of revenue.

Operating margin -923.3% 2024

Net margin -962.1% 2024

Free cash flow margin -2,760.6% 2023

Operating margin
Net margin
Free cash flow margin

Values and sources

Profit margins values and source evidence
Period	Series	Value	Source evidence
2015-09-30	Operating margin	Not reported	Revenue: 3360 Open source
20182018-12-31	Operating margin	-40,031.1%	Operating Income: -2784563 Open source Revenue: 6956 Open source
20192019-12-31	Operating margin	-492.9%	Operating Income: -3458778 Open source Revenue: 701719 Open source
20202020-12-31	Operating margin	-1,760.9%	Operating Income: -8505776 Open source Revenue: 483045 Open source
20212021-12-31	Operating margin	-3,290.1%	Operating Income: -11705968 Open source Revenue: 355797 Open source
20222022-12-31	Operating margin	-1,558.5%	Operating Income: -15114412 Open source Revenue: 969783 Open source
20232023-12-31	Operating margin	-4,439.2%	Operating Income: -6766734 Open source Revenue: 152430 Open source
20242024-12-31	Operating margin	-923.3%	Operating Income: -4705242 Open source Revenue: 509589 Open source
20152015-09-30	Net margin	-960.7%	Net Income: -32281 Open source Revenue: 3360 Open source
20182018-12-31	Net margin	-87,184.2%	Net Income: -6064530 Open source Revenue: 6956 Open source
20192019-12-31	Net margin	-560.5%	Net Income: -3933240 Open source Revenue: 701719 Open source
20202020-12-31	Net margin	-2,193.1%	Net Income: -10593584 Open source Revenue: 483045 Open source
20212021-12-31	Net margin	-3,608.5%	Net Income: -12838813 Open source Revenue: 355797 Open source
20222022-12-31	Net margin	-1,693.5%	Net Income: -16423239 Open source Revenue: 969783 Open source
20232023-12-31	Net margin	-5,109.3%	Net Income: -7788050 Open source Revenue: 152430 Open source
20242024-12-31	Net margin	-962.1%	Net Income: -4902878 Open source Revenue: 509589 Open source
20152015-09-30	Free cash flow margin	Not reported	Revenue: 3360 Open source
20182018-12-31	Free cash flow margin	Not reported	Revenue: 6956 Open source Operating Cash Flow: -900531 Open source
20192019-12-31	Free cash flow margin	Not reported	Revenue: 701719 Open source Operating Cash Flow: -3134526 Open source
20202020-12-31	Free cash flow margin	Not reported	Revenue: 483045 Open source Operating Cash Flow: -4563919 Open source
20212021-12-31	Free cash flow margin	-2,140.3%	Revenue: 355797 Open source Operating Cash Flow: -7597719 Open source Capital Expenditure: 17503 Open source
20222022-12-31	Free cash flow margin	-775.2%	Revenue: 969783 Open source Operating Cash Flow: -7398391 Open source Capital Expenditure: 119692 Open source
20232023-12-31	Free cash flow margin	-2,760.6%	Revenue: 152430 Open source Operating Cash Flow: -4186848 Open source Capital Expenditure: 21201 Open source
20242024-12-31	Free cash flow margin	Not reported	Revenue: 509589 Open source Operating Cash Flow: -1809145 Open source

Operating cash flow

Cash generated by the company’s normal business operations.

USD -1.8M 2024

Values and sources

Operating cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20152015-09-30	Operating cash flow	Not reported	No source recorded
20182018-12-31	Operating cash flow	-900531	Operating Cash Flow: -900531 Open source
20192019-12-31	Operating cash flow	-3134526	Operating Cash Flow: -3134526 Open source
20202020-12-31	Operating cash flow	-4563919	Operating Cash Flow: -4563919 Open source
20212021-12-31	Operating cash flow	-7597719	Operating Cash Flow: -7597719 Open source
20222022-12-31	Operating cash flow	-7398391	Operating Cash Flow: -7398391 Open source
20232023-12-31	Operating cash flow	-4186848	Operating Cash Flow: -4186848 Open source
20242024-12-31	Operating cash flow	-1809145	Operating Cash Flow: -1809145 Open source

Free cash flow

Operating cash flow minus capital expenditure for the same period and unit.

USD -4.2M 2023

Values and sources

Free cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20152015-09-30	Free cash flow	Unavailable	No source recorded
20182018-12-31	Free cash flow	Unavailable	Operating Cash Flow: -900531 Open source
20192019-12-31	Free cash flow	Unavailable	Operating Cash Flow: -3134526 Open source
20202020-12-31	Free cash flow	Unavailable	Operating Cash Flow: -4563919 Open source
20212021-12-31	Free cash flow	-7615222	Operating Cash Flow: -7597719 Open source Capital Expenditure: 17503 Open source
20222022-12-31	Free cash flow	-7518083	Operating Cash Flow: -7398391 Open source Capital Expenditure: 119692 Open source
20232023-12-31	Free cash flow	-4208049	Operating Cash Flow: -4186848 Open source Capital Expenditure: 21201 Open source
20242024-12-31	Free cash flow	Unavailable	Operating Cash Flow: -1809145 Open source

Balance sheet

Liabilities and short-term ability to meet obligations at each period end.

Liabilities to assets

Total liabilities as a share of total assets.

90.4% 2024

Values and sources

Liabilities to assets values and source evidence
Period	Series	Value	Source evidence
20152015-09-30	Liabilities / assets	36.8%	Total Liabilities: 369103 Open source Total Assets: 1002460 Open source
20182018-12-31	Liabilities / assets	189.9%	Total Liabilities: 11280510 Open source Total Assets: 5940124 Open source
20192019-12-31	Liabilities / assets	101.8%	Total Liabilities: 7052628 Open source Total Assets: 6927811 Open source
20202020-12-31	Liabilities / assets	77.1%	Total Liabilities: 8944638 Open source Total Assets: 11606705 Open source
20212021-12-31	Liabilities / assets	35.2%	Total Liabilities: 4827691 Open source Total Assets: 13698033 Open source
20222022-12-31	Liabilities / assets	66.2%	Total Liabilities: 6343435 Open source Total Assets: 9579574 Open source
20232023-12-31	Liabilities / assets	83.9%	Total Liabilities: 6531026 Open source Total Assets: 7784499 Open source
20242024-12-31	Liabilities / assets	90.4%	Total Liabilities: 6815948 Open source Total Assets: 7539907 Open source

Current assets to current liabilities

Current assets divided by current liabilities.

0.33× 2024

Values and sources

Current assets to current liabilities values and source evidence
Period	Series	Value	Source evidence
20152015-09-30	Current assets / current liabilities	25.51×	Current Assets: 998645 Open source Current Liabilities: 39150 Open source
20182018-12-31	Current assets / current liabilities	0.05×	Current Assets: 566476 Open source Current Liabilities: 10987786 Open source
20192019-12-31	Current assets / current liabilities	0.13×	Current Assets: 878238 Open source Current Liabilities: 6814193 Open source
20202020-12-31	Current assets / current liabilities	1.27×	Current Assets: 6172966 Open source Current Liabilities: 4844391 Open source
20212021-12-31	Current assets / current liabilities	2.07×	Current Assets: 7653782 Open source Current Liabilities: 3692312 Open source
20222022-12-31	Current assets / current liabilities	0.54×	Current Assets: 2987247 Open source Current Liabilities: 5543628 Open source
20232023-12-31	Current assets / current liabilities	0.27×	Current Assets: 1656709 Open source Current Liabilities: 6101889 Open source
20242024-12-31	Current assets / current liabilities	0.33×	Current Assets: 2179815 Open source Current Liabilities: 6557461 Open source

Cash generation

Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.

Cash generation by annual reporting period
Period	Net income	Operating cash flow	Capital expenditure	Free cash flow
2016 2015-10-01 – 2016-09-30	−USD 11.01 million Exact value Exact value: -11007799 USD 2015-10-01 – 2016-09-30: -11007799 USD Inspect Net Income Open source Share or cite Citation for Net Income · ABVC BIOPHARMA, INC. · 2016-09-30 ABVC BIOPHARMA, INC. (edgar:1173313) Net Income: -11007799 USD Concept: fundies:NetIncome Period: 2015-10-01 to 2016-09-30 Values: Latest reported Published: 2026-11-02T15:09:01Z Snapshot: 35d14e8488b6344682b1fece4ae225e14dc7c4a5c357b1531821187b936b408c Dimensions: Consolidated View: https://fundies.io/companies/edgar/1173313/explain?concept=fundies%3ANetIncome&period=2016-09-30&surface=latest&period_type=duration&start=2015-10-01&unit=USD&dimensions= Input fundies:NetIncome: -11007799 USD (2015-10-01 to 2016-09-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1173313/000121390018000537/mtoo-20170930.xml#87879 Filing: 000121390018000537 The citation records this snapshot. The page link may show a newer release later.	−USD 3.47 million Exact value Exact value: -3474707 USD 2015-10-01 – 2016-09-30: -3474707 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · ABVC BIOPHARMA, INC. · 2016-09-30 ABVC BIOPHARMA, INC. (edgar:1173313) Operating Cash Flow: -3474707 USD Concept: fundies:OperatingCashFlow Period: 2015-10-01 to 2016-09-30 Values: Latest reported Published: 2026-11-02T15:09:01Z Snapshot: 35d14e8488b6344682b1fece4ae225e14dc7c4a5c357b1531821187b936b408c Dimensions: Consolidated View: https://fundies.io/companies/edgar/1173313/explain?concept=fundies%3AOperatingCashFlow&period=2016-09-30&surface=latest&period_type=duration&start=2015-10-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -3474707 USD (2015-10-01 to 2016-09-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1173313/000121390018000537/mtoo-20170930.xml#398840 Filing: 000121390018000537 The citation records this snapshot. The page link may show a newer release later.	Unavailable Not reported for this period.	Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period.
2017 2016-10-01 – 2017-09-30	−USD 4.07 million Exact value Exact value: -4071983 USD 2016-10-01 – 2017-09-30: -4071983 USD Inspect Net Income Open source Share or cite Citation for Net Income · ABVC BIOPHARMA, INC. · 2017-09-30 ABVC BIOPHARMA, INC. (edgar:1173313) Net Income: -4071983 USD Concept: fundies:NetIncome Period: 2016-10-01 to 2017-09-30 Values: Latest reported Published: 2026-11-02T15:09:01Z Snapshot: 35d14e8488b6344682b1fece4ae225e14dc7c4a5c357b1531821187b936b408c Dimensions: Consolidated View: https://fundies.io/companies/edgar/1173313/explain?concept=fundies%3ANetIncome&period=2017-09-30&surface=latest&period_type=duration&start=2016-10-01&unit=USD&dimensions= Input fundies:NetIncome: -4071983 USD (2016-10-01 to 2017-09-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1173313/000121390018000537/mtoo-20170930.xml#87722 Filing: 000121390018000537 The citation records this snapshot. The page link may show a newer release later.	−USD 1.6 million Exact value Exact value: -1598686 USD 2016-10-01 – 2017-09-30: -1598686 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · ABVC BIOPHARMA, INC. · 2017-09-30 ABVC BIOPHARMA, INC. (edgar:1173313) Operating Cash Flow: -1598686 USD Concept: fundies:OperatingCashFlow Period: 2016-10-01 to 2017-09-30 Values: Latest reported Published: 2026-11-02T15:09:01Z Snapshot: 35d14e8488b6344682b1fece4ae225e14dc7c4a5c357b1531821187b936b408c Dimensions: Consolidated View: https://fundies.io/companies/edgar/1173313/explain?concept=fundies%3AOperatingCashFlow&period=2017-09-30&surface=latest&period_type=duration&start=2016-10-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -1598686 USD (2016-10-01 to 2017-09-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1173313/000121390018000537/mtoo-20170930.xml#398625 Filing: 000121390018000537 The citation records this snapshot. The page link may show a newer release later.	Unavailable Not reported for this period.	Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period.
2017 2017-01-01 – 2017-12-31	−USD 4.24 million Exact value Exact value: -4242860 USD 2017-01-01 – 2017-12-31: -4242860 USD Inspect Net Income Open source Share or cite Citation for Net Income · ABVC BIOPHARMA, INC. · 2017-12-31 ABVC BIOPHARMA, INC. (edgar:1173313) Net Income: -4242860 USD Concept: fundies:NetIncome Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T15:09:01Z Snapshot: 35d14e8488b6344682b1fece4ae225e14dc7c4a5c357b1531821187b936b408c Dimensions: Consolidated View: https://fundies.io/companies/edgar/1173313/explain?concept=fundies%3ANetIncome&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=USD&dimensions= Input fundies:NetIncome: -4242860 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1173313/000121390019006364/abvc-20181231.xml#97770 Filing: 000121390019006364 The citation records this snapshot. The page link may show a newer release later.	−USD 1.49 million Exact value Exact value: -1485313 USD 2017-01-01 – 2017-12-31: -1485313 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · ABVC BIOPHARMA, INC. · 2017-12-31 ABVC BIOPHARMA, INC. (edgar:1173313) Operating Cash Flow: -1485313 USD Concept: fundies:OperatingCashFlow Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T15:09:01Z Snapshot: 35d14e8488b6344682b1fece4ae225e14dc7c4a5c357b1531821187b936b408c Dimensions: Consolidated View: https://fundies.io/companies/edgar/1173313/explain?concept=fundies%3AOperatingCashFlow&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -1485313 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1173313/000121390019006364/abvc-20181231.xml#220639 Filing: 000121390019006364 The citation records this snapshot. The page link may show a newer release later.	Unavailable Not reported for this period.	Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period.
2018 2018-01-01 – 2018-12-31	−USD 6.06 million Exact value Exact value: -6064530 USD 2018-01-01 – 2018-12-31: -6064530 USD Inspect Net Income Open source Share or cite Citation for Net Income · ABVC BIOPHARMA, INC. · 2018-12-31 ABVC BIOPHARMA, INC. (edgar:1173313) Net Income: -6064530 USD Concept: fundies:NetIncome Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T15:09:01Z Snapshot: 35d14e8488b6344682b1fece4ae225e14dc7c4a5c357b1531821187b936b408c Dimensions: Consolidated View: https://fundies.io/companies/edgar/1173313/explain?concept=fundies%3ANetIncome&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:NetIncome: -6064530 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1173313/000121390020012685/abvcd-20191231.xml#185824 Filing: 000121390020012685 The citation records this snapshot. The page link may show a newer release later.	−USD 900,531 Exact value Exact value: -900531 USD 2018-01-01 – 2018-12-31: -900531 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · ABVC BIOPHARMA, INC. · 2018-12-31 ABVC BIOPHARMA, INC. (edgar:1173313) Operating Cash Flow: -900531 USD Concept: fundies:OperatingCashFlow Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T15:09:01Z Snapshot: 35d14e8488b6344682b1fece4ae225e14dc7c4a5c357b1531821187b936b408c Dimensions: Consolidated View: https://fundies.io/companies/edgar/1173313/explain?concept=fundies%3AOperatingCashFlow&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -900531 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1173313/000121390020012685/abvcd-20191231.xml#345239 Filing: 000121390020012685 The citation records this snapshot. The page link may show a newer release later.	Unavailable Not reported for this period.	Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period.
2019 2019-01-01 – 2019-12-31	−USD 3.93 million Exact value Exact value: -3933240 USD 2019-01-01 – 2019-12-31: -3933240 USD Inspect Net Income Open source Share or cite Citation for Net Income · ABVC BIOPHARMA, INC. · 2019-12-31 ABVC BIOPHARMA, INC. (edgar:1173313) Net Income: -3933240 USD Concept: fundies:NetIncome Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T15:09:01Z Snapshot: 35d14e8488b6344682b1fece4ae225e14dc7c4a5c357b1531821187b936b408c Dimensions: Consolidated View: https://fundies.io/companies/edgar/1173313/explain?concept=fundies%3ANetIncome&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:NetIncome: -3933240 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1173313/000121390021015729/abvcd-20201231.xml#565033 Filing: 000121390021015729 The citation records this snapshot. The page link may show a newer release later.	−USD 3.13 million Exact value Exact value: -3134526 USD 2019-01-01 – 2019-12-31: -3134526 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · ABVC BIOPHARMA, INC. · 2019-12-31 ABVC BIOPHARMA, INC. (edgar:1173313) Operating Cash Flow: -3134526 USD Concept: fundies:OperatingCashFlow Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T15:09:01Z Snapshot: 35d14e8488b6344682b1fece4ae225e14dc7c4a5c357b1531821187b936b408c Dimensions: Consolidated View: https://fundies.io/companies/edgar/1173313/explain?concept=fundies%3AOperatingCashFlow&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -3134526 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1173313/000121390021015729/abvcd-20201231.xml#558928 Filing: 000121390021015729 The citation records this snapshot. The page link may show a newer release later.	Unavailable Not reported for this period.	Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period.
2020 2020-01-01 – 2020-12-31	−USD 10.59 million Exact value Exact value: -10593584 USD 2020-01-01 – 2020-12-31: -10593584 USD Inspect Net Income Open source Share or cite Citation for Net Income · ABVC BIOPHARMA, INC. · 2020-12-31 ABVC BIOPHARMA, INC. (edgar:1173313) Net Income: -10593584 USD Concept: fundies:NetIncome Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T15:09:01Z Snapshot: 35d14e8488b6344682b1fece4ae225e14dc7c4a5c357b1531821187b936b408c Dimensions: Consolidated View: https://fundies.io/companies/edgar/1173313/explain?concept=fundies%3ANetIncome&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:NetIncome: -10593584 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1173313/000121390022016726/f10k2021_abvcbio.htm#955211 Filing: 000121390022016726 The citation records this snapshot. The page link may show a newer release later.	−USD 4.56 million Exact value Exact value: -4563919 USD 2020-01-01 – 2020-12-31: -4563919 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · ABVC BIOPHARMA, INC. · 2020-12-31 ABVC BIOPHARMA, INC. (edgar:1173313) Operating Cash Flow: -4563919 USD Concept: fundies:OperatingCashFlow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T15:09:01Z Snapshot: 35d14e8488b6344682b1fece4ae225e14dc7c4a5c357b1531821187b936b408c Dimensions: Consolidated View: https://fundies.io/companies/edgar/1173313/explain?concept=fundies%3AOperatingCashFlow&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -4563919 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1173313/000121390022016726/f10k2021_abvcbio.htm#979502 Filing: 000121390022016726 The citation records this snapshot. The page link may show a newer release later.	Unavailable Not reported for this period.	Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period.
2021 2021-01-01 – 2021-12-31	−USD 12.84 million Exact value Exact value: -12838813 USD 2021-01-01 – 2021-12-31: -12838813 USD Inspect Net Income Open source Share or cite Citation for Net Income · ABVC BIOPHARMA, INC. · 2021-12-31 ABVC BIOPHARMA, INC. (edgar:1173313) Net Income: -12838813 USD Concept: fundies:NetIncome Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T15:09:01Z Snapshot: 35d14e8488b6344682b1fece4ae225e14dc7c4a5c357b1531821187b936b408c Dimensions: Consolidated View: https://fundies.io/companies/edgar/1173313/explain?concept=fundies%3ANetIncome&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:NetIncome: -12838813 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1173313/000121390024014947/ea193878-s1a2_abvcbio.htm#2014368 Filing: 000121390024014947 The citation records this snapshot. The page link may show a newer release later.	−USD 7.6 million Exact value Exact value: -7597719 USD 2021-01-01 – 2021-12-31: -7597719 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · ABVC BIOPHARMA, INC. · 2021-12-31 ABVC BIOPHARMA, INC. (edgar:1173313) Operating Cash Flow: -7597719 USD Concept: fundies:OperatingCashFlow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T15:09:01Z Snapshot: 35d14e8488b6344682b1fece4ae225e14dc7c4a5c357b1531821187b936b408c Dimensions: Consolidated View: https://fundies.io/companies/edgar/1173313/explain?concept=fundies%3AOperatingCashFlow&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -7597719 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1173313/000121390024014947/ea193878-s1a2_abvcbio.htm#2042135 Filing: 000121390024014947 The citation records this snapshot. The page link may show a newer release later.	USD 17,503 Exact value Exact value: 17503 USD 2021-01-01 – 2021-12-31: 17503 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · ABVC BIOPHARMA, INC. · 2021-12-31 ABVC BIOPHARMA, INC. (edgar:1173313) Capital Expenditure: 17503 USD Concept: fundies:CapitalExpenditure Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T15:09:01Z Snapshot: 35d14e8488b6344682b1fece4ae225e14dc7c4a5c357b1531821187b936b408c Dimensions: Consolidated View: https://fundies.io/companies/edgar/1173313/explain?concept=fundies%3ACapitalExpenditure&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 17503 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1173313/000121390024014947/ea193878-s1a2_abvcbio.htm#2044990 Filing: 000121390024014947 The citation records this snapshot. The page link may show a newer release later.	−USD 7.62 million Calculation and evidence -7597719 − 17503 USD Exact free cash flow: -7615222 USD 2021-01-01 – 2021-12-31: -7597719 USD · Inspect Operating Cash Flow · Source 2021-01-01 – 2021-12-31: 17503 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · ABVC BIOPHARMA, INC. · 2021-12-31 ABVC BIOPHARMA, INC. (edgar:1173313) Free cash flow: -7615222 USD Concept: free-cash-flow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T15:09:01Z Snapshot: 35d14e8488b6344682b1fece4ae225e14dc7c4a5c357b1531821187b936b408c Dimensions: Consolidated View: https://fundies.io/companies/edgar/1173313?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -7597719 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1173313/000121390024014947/ea193878-s1a2_abvcbio.htm#2042135 Filing: 000121390024014947 Input fundies:CapitalExpenditure: 17503 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1173313/000121390024014947/ea193878-s1a2_abvcbio.htm#2044990 Filing: 000121390024014947 The citation records this snapshot. The page link may show a newer release later.
2022 2022-01-01 – 2022-12-31	−USD 16.42 million Exact value Exact value: -16423239 USD 2022-01-01 – 2022-12-31: -16423239 USD Inspect Net Income Open source Share or cite Citation for Net Income · ABVC BIOPHARMA, INC. · 2022-12-31 ABVC BIOPHARMA, INC. (edgar:1173313) Net Income: -16423239 USD Concept: fundies:NetIncome Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T15:09:01Z Snapshot: 35d14e8488b6344682b1fece4ae225e14dc7c4a5c357b1531821187b936b408c Dimensions: Consolidated View: https://fundies.io/companies/edgar/1173313/explain?concept=fundies%3ANetIncome&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:NetIncome: -16423239 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1173313/000121390024054857/ea0207987-s1_abvcbio.htm#1699067 Filing: 000121390024054857 The citation records this snapshot. The page link may show a newer release later.	−USD 7.4 million Exact value Exact value: -7398391 USD 2022-01-01 – 2022-12-31: -7398391 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · ABVC BIOPHARMA, INC. · 2022-12-31 ABVC BIOPHARMA, INC. (edgar:1173313) Operating Cash Flow: -7398391 USD Concept: fundies:OperatingCashFlow Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T15:09:01Z Snapshot: 35d14e8488b6344682b1fece4ae225e14dc7c4a5c357b1531821187b936b408c Dimensions: Consolidated View: https://fundies.io/companies/edgar/1173313/explain?concept=fundies%3AOperatingCashFlow&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -7398391 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1173313/000121390024054857/ea0207987-s1_abvcbio.htm#1724452 Filing: 000121390024054857 The citation records this snapshot. The page link may show a newer release later.	USD 119,692 Exact value Exact value: 119692 USD 2022-01-01 – 2022-12-31: 119692 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · ABVC BIOPHARMA, INC. · 2022-12-31 ABVC BIOPHARMA, INC. (edgar:1173313) Capital Expenditure: 119692 USD Concept: fundies:CapitalExpenditure Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T15:09:01Z Snapshot: 35d14e8488b6344682b1fece4ae225e14dc7c4a5c357b1531821187b936b408c Dimensions: Consolidated View: https://fundies.io/companies/edgar/1173313/explain?concept=fundies%3ACapitalExpenditure&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 119692 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1173313/000121390024054857/ea0207987-s1_abvcbio.htm#1726184 Filing: 000121390024054857 The citation records this snapshot. The page link may show a newer release later.	−USD 7.52 million Calculation and evidence -7398391 − 119692 USD Exact free cash flow: -7518083 USD 2022-01-01 – 2022-12-31: -7398391 USD · Inspect Operating Cash Flow · Source 2022-01-01 – 2022-12-31: 119692 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · ABVC BIOPHARMA, INC. · 2022-12-31 ABVC BIOPHARMA, INC. (edgar:1173313) Free cash flow: -7518083 USD Concept: free-cash-flow Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T15:09:01Z Snapshot: 35d14e8488b6344682b1fece4ae225e14dc7c4a5c357b1531821187b936b408c Dimensions: Consolidated View: https://fundies.io/companies/edgar/1173313?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -7398391 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1173313/000121390024054857/ea0207987-s1_abvcbio.htm#1724452 Filing: 000121390024054857 Input fundies:CapitalExpenditure: 119692 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1173313/000121390024054857/ea0207987-s1_abvcbio.htm#1726184 Filing: 000121390024054857 The citation records this snapshot. The page link may show a newer release later.
2023 2023-01-01 – 2023-12-31	−USD 7.79 million Exact value Exact value: -7788050 USD 2023-01-01 – 2023-12-31: -7788050 USD Inspect Net Income Open source Share or cite Citation for Net Income · ABVC BIOPHARMA, INC. · 2023-12-31 ABVC BIOPHARMA, INC. (edgar:1173313) Net Income: -7788050 USD Concept: fundies:NetIncome Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T15:09:01Z Snapshot: 35d14e8488b6344682b1fece4ae225e14dc7c4a5c357b1531821187b936b408c Dimensions: Consolidated View: https://fundies.io/companies/edgar/1173313/explain?concept=fundies%3ANetIncome&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:NetIncome: -7788050 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1173313/000121390025032118/ea0232540-10k_abvcbio.htm#1641972 Filing: 000121390025032118 The citation records this snapshot. The page link may show a newer release later.	−USD 4.19 million Exact value Exact value: -4186848 USD 2023-01-01 – 2023-12-31: -4186848 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · ABVC BIOPHARMA, INC. · 2023-12-31 ABVC BIOPHARMA, INC. (edgar:1173313) Operating Cash Flow: -4186848 USD Concept: fundies:OperatingCashFlow Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T15:09:01Z Snapshot: 35d14e8488b6344682b1fece4ae225e14dc7c4a5c357b1531821187b936b408c Dimensions: Consolidated View: https://fundies.io/companies/edgar/1173313/explain?concept=fundies%3AOperatingCashFlow&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -4186848 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1173313/000121390025032118/ea0232540-10k_abvcbio.htm#875555 Filing: 000121390025032118 The citation records this snapshot. The page link may show a newer release later.	USD 21,201 Exact value Exact value: 21201 USD 2023-01-01 – 2023-12-31: 21201 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · ABVC BIOPHARMA, INC. · 2023-12-31 ABVC BIOPHARMA, INC. (edgar:1173313) Capital Expenditure: 21201 USD Concept: fundies:CapitalExpenditure Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T15:09:01Z Snapshot: 35d14e8488b6344682b1fece4ae225e14dc7c4a5c357b1531821187b936b408c Dimensions: Consolidated View: https://fundies.io/companies/edgar/1173313/explain?concept=fundies%3ACapitalExpenditure&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 21201 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1173313/000121390025032118/ea0232540-10k_abvcbio.htm#877009 Filing: 000121390025032118 The citation records this snapshot. The page link may show a newer release later.	−USD 4.21 million Calculation and evidence -4186848 − 21201 USD Exact free cash flow: -4208049 USD 2023-01-01 – 2023-12-31: -4186848 USD · Inspect Operating Cash Flow · Source 2023-01-01 – 2023-12-31: 21201 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · ABVC BIOPHARMA, INC. · 2023-12-31 ABVC BIOPHARMA, INC. (edgar:1173313) Free cash flow: -4208049 USD Concept: free-cash-flow Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T15:09:01Z Snapshot: 35d14e8488b6344682b1fece4ae225e14dc7c4a5c357b1531821187b936b408c Dimensions: Consolidated View: https://fundies.io/companies/edgar/1173313?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -4186848 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1173313/000121390025032118/ea0232540-10k_abvcbio.htm#875555 Filing: 000121390025032118 Input fundies:CapitalExpenditure: 21201 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1173313/000121390025032118/ea0232540-10k_abvcbio.htm#877009 Filing: 000121390025032118 The citation records this snapshot. The page link may show a newer release later.
2024 2024-01-01 – 2024-12-31	−USD 4.9 million Exact value Exact value: -4902878 USD 2024-01-01 – 2024-12-31: -4902878 USD Inspect Net Income Open source Share or cite Citation for Net Income · ABVC BIOPHARMA, INC. · 2024-12-31 ABVC BIOPHARMA, INC. (edgar:1173313) Net Income: -4902878 USD Concept: fundies:NetIncome Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T15:09:01Z Snapshot: 35d14e8488b6344682b1fece4ae225e14dc7c4a5c357b1531821187b936b408c Dimensions: Consolidated View: https://fundies.io/companies/edgar/1173313/explain?concept=fundies%3ANetIncome&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:NetIncome: -4902878 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1173313/000121390026023063/ea0278313-10k_abvcbio.htm#1163896 Filing: 000121390026023063 The citation records this snapshot. The page link may show a newer release later.	−USD 1.81 million Exact value Exact value: -1809145 USD 2024-01-01 – 2024-12-31: -1809145 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · ABVC BIOPHARMA, INC. · 2024-12-31 ABVC BIOPHARMA, INC. (edgar:1173313) Operating Cash Flow: -1809145 USD Concept: fundies:OperatingCashFlow Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T15:09:01Z Snapshot: 35d14e8488b6344682b1fece4ae225e14dc7c4a5c357b1531821187b936b408c Dimensions: Consolidated View: https://fundies.io/companies/edgar/1173313/explain?concept=fundies%3AOperatingCashFlow&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -1809145 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1173313/000121390026023063/ea0278313-10k_abvcbio.htm#917076 Filing: 000121390026023063 The citation records this snapshot. The page link may show a newer release later.	Unavailable Not reported for this period.	Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period.

Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.

Dataset coverage and company identifiers

Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.

140 filings · 4,092 latest values · 4,084 originally reported values

Dataset published 2026-11-02. Source filing dates and reporting periods are shown separately.

Identifiers: 0001173313, 1173313, ABVC, ABVCD, ECOC, MTOO, edgar:1173313, mtoo

Also known as ABVC BioPharma, Inc., ABVC BIOPHARMA, INC., ABVC BioPharma, Inc, ABVC BioPharma, Inc., American BriVision (Holding) Corp, ECOLOGY COATINGS, INC., Ecology Coatings, Inc., METU BRANDS, INC., Metu Brands, Inc., OCIS CORP

ABVC BIOPHARMA, INC.

Latest quarter

Revenue

Operating margin

Operating cash flow

Trailing twelve months

Operating cash flow

Company performance

What changed year over year

Revenue

Net income

Operating cash flow

Where revenue goes

2024 2024-01-01 – 2024-12-31

Cash

Share of revenue by period

Growth

Profit and cash

Balance sheet

Cash generation